Rodriguez-Tajes, SergioGarcia-Eliz, MaríaCaballero Marcos, ArantxaCampos Varela, IsabelCachero Ros, AlbaLoinaz, CarmeloGómez Bravo, Miguel ÁngelRodríguez Perálvarez, ManuelFabrega, EmilioGonzález Diéguez, María LuisaVinaixa, CarmenPascasio, Juan ManuelFernández Vázquez, InmaculadaBaliellas, CarmenCastells, LluísSalcedo, MagdalenaPrieto Castillo, MartínCrespo Conde, GonzaloLens García, SabelaForns, Xavier2025-01-282025-01-282023-12-151478-3223https://hdl.handle.net/2445/218050Recommended post-liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti-hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real-life clinical practice and its impact on HBV/HDV recurrence in 174 HDV-related LT patients from 10 Spanish liver transplant centres (1988-2018). Median post-LT follow-up was 7.8 (2.3-15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post-LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7-52) months. Post-LT HBsAg+ was detected in 16 (9%) patients and HBV-DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV-LT is feasible, especially if high-barrier NAs are used.7 p.application/pdfengcc-by-nc-nd (c) Rodriguez-Tajes, Sergio et al., 2023https://creativecommons.org/licenses/by-nc-nd/4.0/Hepatitis BTrasplantament hepàticVirus de l'hepatitis deltaHepatitis BHepatic transplantationDelta-associated agentinfo:eu-repo/semantics/article7518362025-01-28info:eu-repo/semantics/openAccess38100141